Company Filing History:
2 out of 179 
1 out of 1 Years Active: 2021-2025
Title: Fumie Abe: Innovator in Antibody Research
Introduction
Fumie Abe is a prominent inventor based in Tsukuba, Japan. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative antibodies. With a total of 2 patents, his work has the potential to impact therapeutic strategies in immunology.
Latest Patents
Fumie Abe's latest patents include a humanized anti-DNAM-1 antibody. This invention features a heavy chain variable region with specific amino acid sequences, as well as a light chain variable region that also contains defined sequences. Another notable patent is a regulatory T cell activator, which includes a substance that inhibits the binding between DNAX accessory molecule-1 (DNAM-1) and CD155. These inventions highlight his expertise in antibody engineering and immune modulation.
Career Highlights
Throughout his career, Fumie Abe has worked with esteemed institutions such as the University of Tsukuba and Tnax Biopharma Corporation. His research has focused on advancing the understanding of immune responses and developing novel therapeutic agents.
Collaborations
Fumie Abe has collaborated with notable colleagues, including Akira Shibuya and Kazuko Shibuya. These partnerships have fostered a collaborative environment that enhances the innovation process in his research endeavors.
Conclusion
Fumie Abe's contributions to antibody research and immunology are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science. His work continues to pave the way for future developments in therapeutic applications.